Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice by Bian, Yingjie et al.
Strong tolerance to hepatitis B virus (HBV) surface antigens limits the therapeutic effect of the conventional hepatitis B
surface antigen (HBsAg) vaccination in both preclinical animal models and patients with chronic hepatitis B (CHB) infec-
tion. In contrast, we observed that clinical CHB patients presented less immune tolerance to the preS1 domain of HBV
large surface antigen. To study whether targeting the weak tolerance of the preS1 region could improve therapy gain, we
explored vaccination with the long peptide of preS1 domain for HBV virions clearance. Our study showed that this
preS1-polypeptide rather than HBsAg vaccination induced robust immune responses in HBV carrier mice. The anti-preS1
rapidly cleared HBV virions in vivo and blocked HBV infection to hepatocytes in vitro. Intriguingly, vaccination of
preS1-polypeptide even reduced the tolerized status of HBsAg, opening a therapeutic window for the host to respond to
the HBsAg vaccine. A sequential administration of antigenically distinct preS1-polypeptide and HBsAg vaccines in HBV
carrier mice could finally induce HBsAg/hepatitis B surface antibody serological conversion and clear chronic HBV infec-
tion in carrier mice. Conclusion: These results suggest that preS1 can function as a therapeutic vaccine for the control of
CHB. (HEPATOLOGY 2017;66:1067-1082)
Persistent HBV infection still represents a sub-stantial threat to public health, despite the exis-tence of effective prophylactic vaccines. More
than 2 billion people are infected with hepatitis B virus
(HBV), and 350 million become chronic HBV carriers
worldwide. Nearly 1 million people die from hepatitis
B–related diseases every year.(1) Thus, there remains an
urgent need for effective treatment strategies to limit
the enormous burden of viral hepatitis on global
health. The HBV genome encodes three overlapping
viral surface antigens, named small (S), middle (M),
and large (L) proteins, respectively. “S protein,” known
as hepatitis B surface antigen (HBsAg), is the common
C-terminal domain of these three proteins, which is
the most abundant surface antigen. M protein is
derived from a transcript initiating at the upstream
start codon of HBsAg. L protein is composed of the
N-terminal preS1 domain and the adjacent M pro-
tein.(2) HBsAg is the most active component of con-
ventional HBV vaccines. Although it elicits strong
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release of HBV virions,(17) making it a potential target
for HBV therapy.
Though the B-cell and T-cell epitopes of the preS1
sequence are well characterized(18-20) and short preS1
peptides have been shown to protect from HBV infec-
tion to the chimpanzee,(21) the tolerized state of preS1
and its unique contribution for vaccination in chronic
HBV infection has not been well defined. Given that
the preS1 domain contains HBV-binding epitopes for
cell entry and exists at much lower levels than HBsAg,
we sought to determine whether it presented a much
weaker tolerized status than that of HBsAg in CHB
hosts, and thus may be feasible to efficiently induce
immune responses to the preS1 domain for protective
anti-HBV immunity. Indeed, we observed both anti-
body and specific T-cell responses to the preS1 region
other than HBsAg in clinical CHB patients. The anti-
preS1 antibody correlated well with the reduction of
preS1 and HBV DNA. In a further study, a murine
CHB model with persistent viremia and immune tol-
erance to the viral antigens was used.(22,23) We
observed that the preS1-polypeptide was a potential
immunogen in HBV carrier mice and its vaccination
could clear HBV virions. Unexpectedly, we observed
that preS1-polypeptide vaccination even reduced the
tolerized status of HBsAg, providing a potential thera-
peutic strategy for treating CHB patients.
Materials and Methods
PATIENTS
In this study, patient clinical information is summa-
rized in Table 1. Sera and peripheral blood
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immunogenicity as a preventive vaccine in healthy peo-
ple, the current HBsAg vaccines cannot induce anti-
body to hepatitis B surface antigen (anti-HBs) for 
viral-clearance in chronic hepatitis B (CHB) pa-
tients.(3) High levels of viral antigens in circulation 
have been shown to induce host immune tolerance 
with impaired dendritic cell, natural killer, or T-cell 
and B-cell functions and thus contribute to HBV per-
sistence.(4-7) How to break or bypass immune tolerance 
and induce anti-HBV immune responses is still a 
major challenge in the development of HBV therapeu-
tic vaccines.
The correlation between high viral antigen load and 
dysfunction of the immune system in chronic infec-
tions has been documented.(7,8) A recent study further 
showed that the threshold of antigen expression is the 
dominant factor in determining the fate of T cells in 
the liver.(9) However, in certain mouse models, studies 
also demonstrated that some antigens of HBV could 
induce effective immune responses because of trace 
expression quantity or high immunogenicity, like the 
HBV nonstructure protein polymerase(10) and the 
“nontolerogen,” hepatitis B core antigen (HBcAg).(11-
13) These implied the potential alternative HBV vac-
cine candidates other than the tolerized HBsAg and 
hepatitis B e antigen (HBeAg) antigens. In HBV 
infection, the defective viral particles containing 
HBsAg generally outnumber infectious HBV virions 
by up to 1,000:1.(2) Unlike HBsAg, the preS1 region 
exists primarily in mature infectious HBV virions and 
thus its level is much lower than that of HBsAg.(14) 
Besides, the preS1 domain mediates the viral inter-
action with the cellular receptor for hepatocyte 
entry(15,16) and plays essential roles in the assembly and
mononuclear cells (PBMCs) isolated from blood sam-
ples of healthy controls (HC; n5 8), acute hepatitis B
(AHB) patients (n5 10), and CHB patients (n5 25)
were collected and stored by the Beijing 302 Hospital
(Beijing, China). Serum levels of anti-HBs and anti-
preS1 were measured by enzyme-linked immunosor-
bent assay (ELISA). HBsAg, HBeAg, and preS1 anti-
gen levels were measured by ELISA. HBV DNA in
serum was measured by qPCR. Consent for collection
of serum and PBMC samples was given by each
patient in writing and authorized by the hospital ethics
review committee.
MICE AND REAGENTS
C57BL/6 mice were purchased from Vital River
Laboratories Animal Technology Co. (Beijing,
China). HLA-A2.1 transgenic mice (C57BL/6-
Tg(HLA-A2.1)1Enge/JNju) were purchased from the
Nanjing Biomedical Research Institute of Nanjing
University (Nanjing, China). Mice were maintained
under specific pathogen-free condition in the BSL-
21 animal facility, and animal experiments were fol-
lowed with protocol no. DWSWAQ (ABSL-2)
2012205 at the Institute of Biophysics, Chinese Acad-
emy of Sciences (Beijing, China). Six- to 8-week-old
male mice were used in all experiments. All animal
experiments were performed in compliance with the
Guidelines for the Care and Use of Laboratory Ani-
mals and were approved by the Biomedical Research
Ethics Committee of the Institute of Biophysics of the
Chinese Academy of Sciences.
Recombinant proteins used in this study include
PreS1 standard-polypeptide (PrimeGene Biotechnol-
ogy Co., Ltd, Shanghai, China), recombinant HBsAg
(rHBsAg; Key-Biotechnology Co., Ltd, Beijing,
China) for vaccination, and HBsAg (ayw serotype; Pri-
meGene Biotechnologya) for Enzyme-Linked Immu-
noSpot (ELISPOT) testing. The large-HBsAg (L-
HBsAg)-containing protein for vaccination was a
commercial product that was purified from patient sera
(Key-Biotechnology). Both the commercial standard
preS1 and the lab-produced preS1 polypeptides are the
proteins of 12 Kdalton and contain only the sequence
of the preS1 domain of HBV large-HBsAg, which is
comprised of preS1, preS2, and S regions. ELISA kits
were used for testing HBsAg, HBeAg (Shanghai
Kehua Bio-engineering Co., Ltd, Shanghai, China),
and preS1 (Shanghai Alpha Biotechnology Co., Ltd,
Shanghai, China). For the ELISA to test anti-preS1,
plates were coated with the commercial standard preS1
protein at 2 mg/mL in phosphate-buffered saline and
samples were added at 1:10, 1;100, and 1:1,000 dilu-
tions. Then, a secondary antibody of goat-anti-mouse
immunoglobulin G (IgG; horseradish peroxidase
[HRP] conjugated; Cwbiotech, Beijing, China) was
added for chromogenic reaction. The purchased anti-
preS1 antibody was an IgG2a monoclonal antibody,
which was raised against HBV preS1 antigen (Santa
Cruz Biotechnology, Santa Cruz, CA). The anti-
preS1 XY007 monoclonal antibody (mAb) was
screened and produced in our lab by yeast display tech-
niques. The peptides for anti-HBs (ayw) testing 111-
140 amino acids (PGSSTTSTGPCRTCMTTAQ
GTSMYPSCCCT) were synthesized by China Pepti-
des Co., Ltd (Shanghai, China).
VIRUS AND ADENO-ASSOCIATED
VIRUS/HBV1.3 INFECTION
The HepG2-hNTCP cell line and HBV-D (sub-
type, ayw) virus were kindly provided by Professor
Wenhui Li (National Institute of Biological Sciences,
Beijing, China). The AAV-HBV1.3 virus was pur-
chased from the Beijing FivePlus Molecular Medicine
Institute (Beijing, China). This recombinant virus car-
ries 1.3 copies of the HBV genome (genotype D, sero-
type ayw) and is packaged in adeno-associated virus
(AAV) serotype 8 capsids. Adult C57BL/6 and
C57BL/6-Tg (HLA-A2.1) mice were injected with
TABLE 1. Clinical Characteristics of Study Cohort
Patients
Age
(years 6 SD)
Sex
(n 5 Male,
%)
Viremia
(IU/mL,
6 SD)
HBeAg
(n 5 Positive,
%)
Anti-HBeAg
(n 5 Positive,
%)
ALT
(IU/mL 6 SD)
AST
(IU/mL 6 SD)
HC (n 5 8) 44.43 6 13.66 n 5 4, 50 —* n 5 0, 0 —* —* —*
AHB (n 5 10) 34.78 6 11.44 n 5 6, 60 1.46E106 6
2.99E106
n 5 2, 20 n 5 8, 80 757.00 6
437.67
337.78 6
302.92
CHB (n 5 25) 25.2 6 8.89 n 5 19, 76 1.55E108 6
1.5E108
n 5 25, 100 n 5 0, 0 225.28 6
337.88
110.24 6
126.34
*Data not tested.
Liver HBV DNA was extracted from 50mg of liver
tissue using a gDNA kit (Tiagen Biotech, Beijing,
China). Total RNA was extracted from livers of
AAV-HBV1.3-infected mice with TRIzol reagent
(Invitrogen, Carlsbad, CA, USA). RNA was reverse-
transcribed (RT-PCR) using the RevertAid First
Strand cDNA synthesis Kit (Thermo Scientific, Wal-
tham, MA, USA). Samples were analyzed by using
qPCR with the following HBV-specific primers:
HBV-HBsAg–real–F:50-CACATCAGGATTCCTA
GGACC-30; HBV-HBsAg-real-R: 50-GGTGAGT
GATTGGAGGTTG-30. HBV-3.5kb-real-F:50-GA
GTGTGGATTCGCACTCC- 30; HBV-3.5kb-real–
R:50-GAGGCGAGGGAGTTCTTCT-30. HBV-
total-real-F:50-TCACCAGCACCATGCAAC-30;
and HBV-total-real-R:50-AAGCCACCCAAGGCA
CAG-30. Real- time PCR was performed using the
SYBR Premix Ex Taq kit (Takara, Japan) with an ABI
Fast 7500 Real-Time PCR System.
HBV INFECTION AND
INHIBITION ASSAYS
IN VITRO
In vitro HBV infection and inhibition assays were
performed as reported.(16) Briefly, 13 107 copies of
genome-equivalent HBV were inoculated into culture
medium of 13 105 HepG2-hNTCP cells in 48-well
plates in the presence of the preS1 antibody or anti-
preS1 serum and incubated for 24 hours. Cells were
then washed with medium three times and maintained
in primary hepatocytes maintenance medium (PMM)
medium (William’s E medium [Gibco, Waltham, MA,
USA] with 5lg/mL of transferrin, 5 ng/mL of sodium
selenite, 3lg/mL of insulin [insulin/transferrin/sodium
selenite; Corning, NY, USA], 2mM of L-glutamine,
10 ng/mL of epidermal growth factor [Sigma-Aldrich,
St Louis, MO, USA], 2% dimethyl sulfoxide, 100 U/
mL of penicillin, and 100lg/mL of streptomycin).
Medium was changed every 2 days. Viral infection at
different time points was analyzed by measuring viral
antigen and viral RNAs in culture medium.
ELISPOT ASSAY
Lymph nodes (LNs), spleen, and liver were har-
vested at the indicated time points after immunization
with rHBsAg or preS1-polypeptide vaccines. Intrahe-
patic lymphocytes were isolated by enzymatic diges-
tion. Briefly, liver tissues were digested by collagenase
IV (Roche, Basel, Switzerland) at 378C for 15 minutes.
the experimentally indicated amounts of recombinant 
virus (diluted to 200 mL with saline) by tail vein injec-
tion. After 4 weeks or more, stable HBV carrier mice 
were used for vaccination.(22) Mice were bled through 
the ophthalmic vein at the indicated time points in the 
respective experiments to monitor HBsAg, HBV 
preS1 antigen (preS1), HBs antibody, preS1 antibody, 
and HBV genomic DNA (gDNA) in serum.
PreS1-POLYPEPTIDE VACCINE
PREPARATION
The coding sequence of preS1-polypeptide was syn-
thesized by PCR from complimentary DNA (cDNA) 
extracted from livers of AAV-HBV1.3-infected mice. 
We used the following primers: 50-CGGGATCCat 
ggggcagaatctttccacca and 30-CCGCTCGAGctaggcct 
gaggatgagtgtttct.(24) Then, the sequence was subcloned 
into plasmid SUMO-pET-28a to yield the expression 
plasmid. The plasmid was transformed into Escherichia 
coli BL21(DE3) cells. Expression of fusion protein was 
induced by 1 mmol/L of isopropyl-beta-D-thiogalacto-
pyranoside at 378C and left overnight. Then, the 
induced cells were harvested and sonicated. The super-
natant of the cell lysates was purified by Ni-NTA (GE 
Healthcare, Wilkes-Barre, PA) column chromatogra-
phy. Finally, the 6 3 His-SUMO (Small Ubiquitin 
MOdifier) tag was cut by SUMO-protease, and preS1 
was separated by molecular size exclusion and ion-
exchange chromatography (Superdex-75, and HiTrap 
QFF; GE Healthcare).
VACCINATION
Alum adjuvant (Alhydrogel 2%) and MPLA Syn-
thetic VacciGrade were purchased from InvivoGen 
(Toulouse, France). CpG-1826 (TCCATGACGTT 
CCTGACGTT) was synthesized by Life Technolo-
gies Corporation (Carlsbad, CA, USA). Incomplete 
Freund’s adjuvant (IFA) was purchased from Sigma-
Aldrich (St. Louis, MO, USA) (Supporting Fig. S1). 
The adjuvants were mixed with 5 mg of rHBsAg or 
10 mg of preS1 for use in vaccination. All vaccines were 
injected subcutaneously.
HBV-DNA AND RNA
DETECTION
Serum HBV DNA was extracted from 200 mL of  
serum and measured following the manufacturer’s 
instructions (careHBV; Qiagen, Hilden, Germany).
correlation test. A value of P< 0.05 was considered a
statistically significant correlation.
Results
PreS1 DOMAIN PRESENTS MORE
IMMUNOGENICITY THAN HBsAg
IN CLINICAL CHB PATIENTS
To dissect the tolerized status toward preS1 domain
and HBsAg in HBV infection, we compared the levels
of antigens and antibodies in clinical HBV patients.
We observed that preS1 antigen presented in much
less quantity (10-fold) than HBsAg in serum (Fig.
1A). Anti-preS1, but not anti-HBs, was detectable in
both AHB and CHB patients (Fig. 1B), correspond-
ing to the specific T-cell response to preS1 domain,
but not HBsAg, in CHB patients (Fig. 1C). All these
suggest that CHB hosts have less tolerance toward the
preS1 domain than HBsAg.
In the clinic, the appearance of anti-preS1 in patients
implies a better recovery from AHB.(25-27) So, we inves-
tigated whether there were relationships between anti-
preS1 and reduction of HBV infection. We observed
that anti-preS1 was negatively correlated with preS1
antigen (Fig. 1D), as well as HBV DNA (Fig. 1E). The
results implied that the immune responses to the preS1
domain might be associated with a potential recovery
from CHB infection. All these raise the possibility that
preS1, presenting in less quantity, together with its
essential role in formation of HBV virion, might serve as
an immunogenic antigen and thus be an effective thera-
peutic vaccine to clear HBV virions in CHB infection.
THE LEVEL OF PreS1 ANTIGEN
IS SIGNIFICANT LOWER THAN
THAT OF HBsAg IN THE MURINE
HBV MODEL
We have reported a murine model with intravenous
infection of AAV-HBV1.3, which partially mimics
immunological characteristics of chronic HBV infec-
tion.(22,23) Tolerance to HBsAg was induced by its level
in serum and could be reversed by reducing its titer with
a neutralizing mAb, leading to immune responses to the
conventional HBsAg vaccine.(28) We compared the
antigen levels of preS1 and HBsAg in the same model.
PreS1 antigen was 10-fold lower than HBsAg in the
peripheral (Fig. 2A), regardless of the HBV infection
doses (Fig. 2B), similar to that in clinical patients. We
The suspension was centrifuged at 30g for 1 minute to 
remove hepatocytes. Lymphocytes were then pelleted 
by centrifugation at 400g for 10 minutes and further 
purified with 40% and 70% Percoll solutions by centri-
fugation at 800g for 20 minutes at room temperature. 
Cells were collected from the interface, and red 
blood cells were removed with ammonium-chloride-
potassium buffer to make a single-cell suspension.
CD4-deleted and CD8-deleted lymphocytes were 
collected through magnetic separation with anti-APC 
(allophycocyanin) Microbeads (Miltenyi Biotec Inc., 
Bergisch Gladbach, Germany), following the manufac-
turer’s protocol. Briefly, splenocytes were first stained 
with the APC-conjugated primary antibody, and cells 
were then magnetically labeled with anti-APC microbe-
ads. Then, the cell suspension was loaded onto a mag-
netic cell separation system (MACS) column, which 
was placed in the magnetic field of a MACS separator. 
The magnetically labeled CD41 or CD81 cells were 
retained within the column. The unlabeled cells were 
collected as CD4-deleted or CD8-deleted cells.
PBMCs from HBV patients were stored in liquid 
nitrogen. And after being thawed at 378C, lymphocytes 
were pelleted by centrifugation at 400g for 5 minutes in 
10 mL of complete medium. Then, cells were put into 
medium to make a single-cell suspension. For detecting 
antigen-specific immune response, lymphocytes were 
incubated for 48 hours at 378C in complete medium 
containing full-preS1 protein or HBsAg peptide pools 
that covers all identified HBsAg T-cell epitopes in an 
interferon-gamma (IFNc) ELISPOT plate (Merck  
Millipore, Billerica, MA). After incubation, the IFN-c 
secretion was analyzed using a biotinylated anti-IFN-c 
antibody and streptavidin-HRP (BD Biosciences, 
Franklin Lakes, NJ). Finally, the spots were visualized 
with 30-amino-9-ethylcarbazole substrate and quantified 
with an autoanalyzing system.
STATISTICAL ANALYSIS
Error bars in data represent mean 6 SEM. Data 
were analyzed using an unpaired two-tailed t test or 
two-way analysis of variance (ANOVA) by the Graph-
Pad Prism statistical software (GraphPad Software 
Inc., San Diego, CA, USA). A value of P < 0.05 was 
considered statistically significant (*P < 0.05; 
**P < 0.01; ***P < 0.001; and ****P < 0.0001). The cor-
relation between HBsAg and preS1, anti-preS1 and 
preS1, and anti-preS1 and HBV DNA in clinical 
HBV patients was analyzed using two-tailed
also observed that preS1 antigen presented in much less
quantity than HBsAg in liver (Fig. 2C).
PreS1 domain has been reported to be contained
mainly on HBV virions in clinical samples.(14) To con-
firm this in the murine model, HBV carrier mice were
intraperitoneally injected with the mAb, XY007, spe-
cific to the preS1 region. We observed that XY007
efficiently cleared both serum preS1 antigen and HBV
DNA to an undetectable level, but there was no signif-
icant change for level of HBsAg (Fig. 2D). Thus, the
preS1 antigen presents in low quantity in the HBV
murine model, similar to that in CHB patients. All
these raises the possibility that preS1 might function as
a potential breakthrough point for breaking HBV
immune tolerance.
PreS1 DOMAIN IS NOT
TOLERIZED IN HBV
CARRIER MICE
We first determined the immunogenicity of the
preS1 domain by vaccinating C57BL/6 mice with
preS1-polypeptide formulated in the indicated adju-
vants (Supporting Fig. S1). Then, the immune
responses of preS1-polypeptide vaccine and the con-
ventional HBsAg vaccine were compared in HBV car-
rier mice. As mentioned, though HBsAg vaccine
elicits strong immune response in wild-type (WT)
mice, it did not induce HBsAb seroconversion in car-
rier mice (Fig. 3A). And there was no induction of
specific T-cell response to HBsAg in contrast to its
FIG. 1. PreS1 domain is less immune tolerized than HBsAg in CHB patients. (A) HBsAg and preS1 antigen levels in CHB patients 
(n 5 25) were tested by ELISA. The correlation between HBsAg and preS1 was analyzed using a two-tailed correlation test. (B) 
Anti-HBs and anti-preS1 in HC (n 5 8), AHB (n 5 10), and CHB (n 5 25) were tested by ELISA (dilution 1:10). (C) PBMCs 
from patients (AHB, n 5 2; CHB, n 5 14) were collected and then stimulated with 5 mg/mL of HBsAg or preS1. Specific T-cell 
response to HBsAg and preS1 were tested by IFN-c secreting ELISPOT. (D,E) In CHB patients, the correlation between anti-
preS1 (OD450-630) and preS1 (log10 ng/mL) and the correlation between anti-preS1 (OD450-630) and HBV DNA (log10 IU/mL) 
were analyzed. Error bars in data represent mean 6 SEM. *P < 0.05; **P < 0.01; ****P < 0.0001 by a two-tailed correlation test 
(A,D,E) or unpaired t test (B). Abbrevistion: OD, optical density.

robust immune response observed in WT mice (Fig.
3B). Thus, inducing HBsAb is a challenging clinical
goal for the conventional HBsAg vaccine to achieve
because of the immune tolerance induced by the circu-
lating HBsAg.
However, unlike the tolerized HBsAg antigen,
HBV carriers that were vaccinated with preS1-
polypeptide generated specific antibodies to the
preS1 domain, the level of which is comparable to
that in WT mice (Fig. 3C). We also determined the
specific T-cell responses to the preS1 region in
draining LN, spleen, and liver after preS1-
polypeptide vaccination, all of which were similar to
the responses developed in WT mice (Fig. 3D).
These results suggest that, contrary to HBsAg, the
preS1 domain is not a viral tolerogen in the HBV
carrier model and could be used as a therapeutic vac-
cine for CHB infection.
PreS1-POLYPEPTIDE
VACCINATION EFFECTIVELY
PREVENTS HBV INFECTION
In the clinical setting, the preS1 domain alone had
never been used as a preventive vaccine for HBV infec-
tion. To determine whether preS1-polypeptide
FIG. 2. PreS1 antigen is much lower than HBsAg in HBV carrier mice. (A) C57BL/6 mice (n54/group, 6-8 weeks old, male) were 
intravenously infected with 1 3 1010 viral genome equivalents(vg) of AAV-HBV1.3 viruses in 200 mL of saline. Blood samples were 
collected every week after infection. Antigen levels of HBsAg and preS1 were detected by ELISA. (B) Three doses of virus ranging 
from 2 3 109 to 1 3 1010vg were delivered to C57BL/6 mice (n 5 3/group, 6-8 weeks old, male). Four weeks later, the antigen level 
in the serum was measured by ELISA. (C) C57BL/6 mice were infected with 1 3 1010 vg of viruses. Mice were sacrificed to collect 
liver tissue 8 weeks later. Protein levels of preS1 antigen and HBsAg in grinded tissue were detected by ELISA. (D) Carrier mice 
were intraperitoneally injected with 200 mg of mAb XY007 specific to the preS1 domain, and 1 day later, preS1 and HBsAg antigen 
levels in serum were tested by ELISA; HBV DNA in serum was extracted and was tested by qPCR as the manufacturer mentioned. 
One representative result of three independent experiments for panel A (N 5 12/group), or four for panel B (N 5 16/group), or three 
for panel D (N 5 15/group) is shown. Error bars in data represent mean 6 SEM. “ns” means “no significant difference.” *P < 0.05; 
***P < 0.001; ****P < 0.0001 by two-way ANOVA (A) or unpaired t test (B,C,D). Abbreviation: hIgG, human immunoglobulin G.
vaccination could be used for HBV prevention, mice
were inoculated subcutaneously with preS1-
polypeptide as the indicated time schedule in Fig. 4A.
This vaccination induced preS1-specific antibody (Fig.
4B) and cleared the preS1 antigens in serum after
AAV-HBV infection, similar to the clinical HBsAg
vaccination (Fig. 4C). Most important, the HBV
DNA in serum was also undetectable at the end of the
experiment (Fig. 4D), indicating the viral clearance by
endogenous antibody to the preS1 domain. These
results demonstrate that preS1-polypeptide vaccination
can effectively prevent HBV infection in vivo.
As HBV is a hepadnavirus that infects only humans
and a few primates,(29) mouse models cannot be used
to test the direct HBV infection/reinfection to the host
liver in vivo. To investigate whether the preS1 antisera
could block HBV entry/re-entry to hepatocytes, we
infected HepG2-hNTCP cells with HBV viruses in
the presence of anti-preS1 serum and incubated for 24
hours (Fig. 4E), as reported.(16) The production of
both HBsAg and HBeAg in cell culture media was
significantly reduced when anti-preS1 serum was
added, but not the control antibody (Fig. 4F). It indi-
cated that the HBV infection to hepatocytes was
FIG. 3. Unlike HBsAg, the preS1 domain is not tolerized in HBV carrier mice. C57BL/6 (n 5 4/group, 6-8 weeks old, male) WT, 
and stable HBV carrier mice were vaccinated with preS1-polypeptide or HBsAg formulated in IFA adjuvant, respectively. (A) Anti-
HBs in serum after HBsAg vaccination in WT and carrier mice were determined at the indicated time points by ELISA. (B) In 
HBsAg-vaccinated WT and carrier mice, 2 3 105 lymphocytes from LN and spleen were collected 28 days after the second vaccina-
tion. Then, cells were stimulated with 5 mg of full-length HBsAg or BSA, and the specific T-cell responses to HBsAg were tested by 
IFN-c ELISPOT. (C) Anti-preS1 in serum after preS1-polypeptide vaccination in WT and carrier mice were determined at the indi-
cated time points by ELISA. (D) In preS1-polypeptide-vaccinated WT and carrier mice, 2 3 105 lymphocytes from LN, spleen, and 
liver were collected 28 days after the second vaccination. Then, cells were stimulated with 5 mg of preS1 polypeptide or BSA. Specific 
T-cell responses to the preS1 domain were tested by IFN-c ELISPOT. One representative result of three (WT mice, N 5 14) or four 
(carrier mice, N 5 14) independent experiments is shown. Error bars in data represent mean 6 SEM. “ns” means “no significant differ-
ence.” ****P < 0.0001 by two-way ANOVA (A,C) or unpaired t test (B,D). Abbreviations: BSA, bovine serum albumin; OD, optical 
density.
FIG. 4. PreS1-polypeptide functions as an effective preventive vaccine for HBV infection. (A) Time schedule for preS1-polypeptide 
vaccination to prevent HBV infection. (B) Only anti-preS1, but no anti-HBs, was detected after preS1 vaccination and HBV infection 
in preS1-polypeptide-vaccinated mice. (C) PreS1 antigen level in serum after HBV infection was tested by ELISA. (D) HBV DNA 
in serum was extracted per the manufacturer’s instructions and tested by qPCR. (E) Schematic diagram of blocking HBV infection to 
hepatocytes in vitro. Briefly, HepG2-hNTCP cells were inoculated with 1 3 107 genome equivalents of HBV in the presence of anti-
preS1 serum or control mouse IgG and incubated for 24 hours. Then, cells were washed with medium three times and maintained in 
PMM medium. The supernatant of the culture was collected and medium was changed every 2 days. Levels of HBsAg (F) and 
HBeAg (G) in the supernatant were measured by ELISA. HBV viral RNAs in infected cells were extracted at the indicated time 
points; HBV-specific 3.5-kb RNA (H) and HBV total RNA (I) were quantified by qPCR. One representative result of three indepen-
dent experiments is shown for panels A, B, C, and D (N 5 12/group) and for panels E, F, G, H, and I (N518 wells/group). Error 
bars in data represent mean 6 SEM. “ns” means “no significant difference.” *P < 0.05 by unpaired t test (D,H,I). Abbreviations: IgG, 
immunoglobulin G; OD, optical density.
ADMINISTRATION OF PreS1-
POLYPEPTIDE PARTIALLY
RESTORES HOST IMMUNE
RESPONSES TO HBsAg
In the study of applying preS1-polypeptide as pre-
ventive vaccination for HBV infection, we unexpect-
edly observed that the level of HBsAg significantly
decreased (Fig. 6A). However, we could not detect sig-
nificant anti-HBsAg in serum (Fig. 4B). The decrease,
but not clearance, of HBsAg may result from the weak
anti-HBsAg response induced by preS1-polypeptide
vaccination, which could not completely neutralize the
large-scale HBsAg circulating in serum. To test this
hypothesis, we detected the specific B-cell response to
HBsAg by ELISPOT and observed that preS1-
polypeptide vaccination indeed induced HBsAg-
specific antibody response (Fig. 6B). Given that the
preS1 domain is always coexisting with HBsAg in
HBV L-HBsAg during infection, the nontolerized
preS1-specific T cells could cross-reactivate the toler-
ized B cells to HBsAg,(20) which thus might partially
restore host immune response toward HBsAg. To test
the hypothesis, we detected the serum level of HBsAg
in carrier mice after preS1 vaccination. Intriguingly,
the preS1-polypeptide vaccination definitely reduced
HBsAg (Fig. 6C) and induced the specific B-cell
response to HBsAg, even in HBV carrier mice
(Fig. 6D).
Thus, we proposed that preS1 vaccination may open
a therapeutic window for the hosts who are deeply
tolerized to the HBsAg vaccine. We designed a
sequential vaccine of preS1-polypeptide before HBsAg
in HBV carrier mice to test this hypothesis. The vacci-
nation schedule was as shown in Fig. 7A. Compared
to HBsAg vaccination alone, the priming with preS1-
polypeptide before HBsAg vaccine cleared both preS1
and HBsAg antigens in HBV carrier mice (Fig. 7B).
We determined the antibody in serum and observed
that such a combination induced specific B-cell
response to HBsAg and made anti-HBs seroconver-
sion (Fig. 7C), a marker for clinical cure to CHB
infection. And, most important, specific T-cell res-
ponse to HBsAg could also be detected both in spleen
and liver (Fig. 7D). The specific T-cell response
induced the reduction both of the HBV RNAs and
DNA in hepatocytes (Fig. 7E-G). This response to
HBsAg was also accompanied by the diminished
immunohistochemical (IHC) staining of HBV core
antigen in the liver (Fig. 7H). Thus, the strategy of
priming with preS1 before HBsAg vaccination might
blocked by antisera to the preS1 domain. This was fur-
ther demonstrated by the reduction of HBV viral repli-
cative intermediates, including the 3.5-kilobase (kb) 
HBV RNA and the total HBV RNA (Fig. 4G). 
To further confirm that anti-preS1 alone could 
inhibit the infection and subsequent replication of 
HBV in hepatocytes, we repeated the experiment by 
mAb XY007 (Supporting Fig. S2). Thus, using the 
murine HBV model and HepG2-hNTCP infection 
system, we demonstrated that preS1-polypeptide was 
potentially an effective vaccine for preventing HBV 
infection.
PreS1-POLYPEPTIDE SERVES
AS A THERAPEUTIC VACCINE
IN HBV CARRIER MICE
To determine the therapeutic effects of preS1 poly-
peptide vaccine, we challenged HBV carrier mice with 
preS1 vaccine, and boosted with the same dose 14 days 
later. Antigen and antibody responses were tested at 
the indicated time points (Fig. 5A). As mentioned, 
HBsAg vaccine could not induce immune response in 
HBV carrier mice. Even on 35 days postvaccination 
with HBsAg, none of the carrier mice showed a signif-
icant reduction in preS1 antigen (Fig. 5B) and HBV-
DNA in serum (Fig. 5C). On the contrary, preS1-
polypeptide vaccination induced anti-preS1 immune 
response, and then preS1 antigen decreased sharply 
after induction of anti-preS1. It was cleared completely 
on day 14 postvaccine boost (Fig. 5B). Moreover, anti-
preS1 resulted in HBV-DNA clearance in serum (Fig. 
5C). The in vitro HBV inhibition assay showed that 
anti-preS1 in HBV carrier mice resulted in a signifi-
cant reduction in the secretion of HBsAg and HBeAg 
in the HepG2-hNTCP cell in vitro system (Fig. 5D). 
RNA levels of HBV in HepG2-hNTCP also indicated 
that anti-preS1 induced in carrier mice blocked 
HBV infection/reinfection to hepatocytes efficiently 
(Fig. 5E).
We repeated the experiment in the HLA-A2.1/
transgenic HBV carrier mice model.(23) The same as in 
the C57BL/6 carrier model, vaccination with preS1 
polypeptide, rather than HBsAg, induced clearance 
of the preS1 antigen. ELISPOT results for T-cell 
response corresponded well to antibody response (Sup-
porting Fig. S3). Together, these results indicated that 
preS1 antigen is not tolerized in HBV carrier mice. 
The viral-specific immune response to the preS1 
domain can clear HBV viral particles and potentially 
block HBV infection/reinfection to hepatocytes.
serve as an effective treatment for clinical CHB virus
infection in the future.
Discussion
In this study, we have explored whether preS1-
polypeptide vaccination is a potential treatment for
CHB infection. We first analyzed the levels of preS1
antigen and HBsAg in clinical HBV patients and
compared the immunogenicity of these two viral anti-
gens in HBV carrier mice. The preS1 domain of L-
HBsAg presents strong immunogenicity for both B-
cell and T-cell responses in contrast to HBsAg, the
major toleragen in CHB patients. Actually, the appear-
ance of anti-preS1 indicated a potential recovery from
HBV infection. By using the HBV carrier model, we
confirmed the immunogenicity of preS1 polypeptide.
The anti-preS1 induced by preS1-polypeptide
cleared HBV DNA in carrier mice and blocked HBV
infection/reinfection to hepatocytes. Furthermore,
preS1-polypeptide vaccination even weakened HBsAg
tolerized status and the subsequent vaccination with
HBsAg could induce anti-HBs seroconversion in
HBV carrier mice.
Unlike preS1 polypeptide, HBsAg has been widely
used as a prophylactic vaccine against HBV, but it can-
not induce immune responses to clear HBsAg in CHB
patients and even in some healthy recipients.(4,30-32)
To further enhance vaccine immunogenicity and
immune protection from HBV infection, the L-
HBsAg containing preS1 domain has been included in
FIG. 5. PreS1-polypeptide functions as therapeutic vaccine in HBV in carrier mice. (A) Time schedule for testing preS1 antigen tol-
erance in HBV carrier mice. C57BL/6 (n 5 4/group, 6-8 weeks old, male) WT, and stable HBV carrier mice were vaccinated with 
preS1-polypeptide or HBsAg formulated in IFA adjuvant, respectively. (B) After preS1-polypeptide or HBsAg vaccination in carrier 
mice, preS1 antigen levels in serum were determined by ELISA at the indicated time points. (C) HBV DNA in serum of each group 
was extracted and determined by qPCR. (D) Anti-sera induced in HBV carrier mice with preS1 vaccination blocked HBV infection 
to HepG2-hNTCP in vitro. Levels of HBsAg and HBeAg in supernatants were measured by ELISA at the indicated time points. (E) 
Total RNAs of infected cells were extracted on day 10 of HBV infection in vitro, and HBV-specific RNAs were measured with 
qPCR. One representative result of four independent experiments is shown for panels A and B (N 5 21/group), three for panel C 
(N 5 12/group), and three for panels D and E (N 5 12 wells/group). Error bars in data represent mean 6 SEM. “ns” means “no sig-
nificant difference.” *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by two-way ANOVA (B) or unpaired t test (C,D,E). Abbrevia-
tions: IgG, immunoglobulin G; OD, optical density.
the third-generation HBV vaccines.(33-35) However, by
using the HBV carrier mouse model, we observed that,
same as the conventional HBsAg vaccine, the L-
HBsAg-containing protein vaccination showed no
therapeutic effects in the tolerized model either
(Supporting Fig. S4). Failing in induction of immune
response to the preS1 domain by the L-HBsAg-
containing protein vaccination might be attributed to
an overwhelming immune tolerance to HBsAg, a
physical link of preS1 domain to HBsAg, or too little
amount of preS1 region containing in the vac-
cine.(36,37) It is also possible that alum, the currently
clinically used adjuvant, might not be potent enough
to induce detectable responses. Whether the preS1
region itself alone can be applied as a vaccine has not
been directly tested. Here, we found that the antige-
nicity of preS1 was weaker than that of HBsAg; it can
only induce robust responses with stronger adjuvants,
FIG. 6. PreS1-polypeptide vaccination induce the B-cell response to HBsAg in HBV mice. (A) After preS1-polypeptide vaccination, mice 
were infected with HBV and the level of HBsAg in serum was tested by ELISA, which indicated that preS1 prevaccination diminished 
HBsAg level in serum. (B) In preS1-prevaccinated mice, 2 3 105 splenocytes were collected 28 days after HBV infection. Specific B-cell 
response to HBsAg was tested by B-cell ELISPOT assay. (C) In HBV carrier mice, preS1-polypeptide was vaccinated at days 28 and 42 
after AAV-HBV inoculation. HBsAg variations in carrier mice were tested by ELISA. (D) In preS1-polypeptide-vaccinated HBV carrier 
mice, 2 3 105 splenocytes were collected. Specific B-cell response to HBsAg was tested by B-cell ELISPOT assay. One (A,B,C) or two 
(D) representative results of three (N 5 11/group) independent experiments are shown. Error bars in data represent mean 6 SEM. *P < 
0.05; **P < 0.01 by two-way ANOVA (A,C) or one-tailed t test (B,D). Abbreviation: i.v, intravenous.
FIG. 7. HBsAg boost immunization amplifies preS1-polypeptide-induced anti-HBV response for viral clearance. (A) Time schedule 
for preS1-polypeptide combination with HBsAg as vaccine to treat HBV carrier mice. (B) After carrier mice were vaccinated with 
preS1-polypeptide1HBsAg, the preS1 and HBsAg antigens in serum were tested by ELISA. (C) B-cell response to HBsAg was 
tested by B-cell ELISPOT, and anti-HBs in serum was tested by ELISA. (D) Mice were sacrificed on the last day, and 2 3 105 lym-
phocytes from LN, spleen, and liver were collected. Then, cells were stimulated with 5 mg of preS1 polypeptide, HBsAg, or BSA, and 
specific T-cell response was measured by IFN-c secretion T-cell ELISPOT assay. (E) HBV total RNAs and (F) intermediate prod-
ucts 3.5-kb RNA in liver tissue were determined with qPCR. (G) HBV DNA in liver was determined by qPCR. (H) IHC staining 
for HBcAg in hepatocytes (Magnification: 200X). One representative result of three (N 5 11/group; B,C,D) or two (N 5 7; E,F,G,H) 
independent experiments are shown. Error bars in data represent mean 6 SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by 
two-way ANOVA (B,C) or unpaired t test (D,E,F,G). Abbreviations: Ad, adenovirus; BSA, bovine serum albumin; i.v, intravenous; 
OD, optical density.
HBV reinfection to healthy hepatocytes in patients,
and thus dilute and even diminish the HBV-infected
hepatocytes gradually. Unexpectedly, we observed that
preS1-polypeptide vaccination partially restored im-
mune response to HBsAg during HBV infection and
thus opened a therapeutic window for the host to fully
respond to the HBsAg vaccine. To amplify the
response to HBsAg induced by preS1-polypeptide vac-
cination and induce stronger and multispecific T-cell
responses for complete viral clearance in HBV carrier
mice, the sequential combination of preS1-polypeptide
before the HBsAg vaccination was administered. We
showed that preS1-polypeptide priming before vacci-
nation with HBsAg restored both the B-cell and T-
cell response to HBsAg in the periphery and liver, ulti-
mate resulting in the HBsAb seroconversion and grad-
ual clearance of HBV in the liver. IHC staining also
showed a dramatic decrease in the number of core-
positive hepatocytes in livers of HBV carrier mice.
This strategy indeed makes HBsAg, the preventive
vaccine, achieve an unexpected therapeutic effect in
HBV carrier mice. However, it is not yet clear how
preS1 region vaccination helped to restore immune
response to HBsAg. In HBV infection, the preS1
domain is always fused with HBsAg within L-HBsAg;
thus, T cells to the preS1 region may help in the
immune response to HBsAg.(20,43) Moreover, the
immune complex of endogenous anti-preS1 with HBV
virions may further enhance anti-HBV immune
response. The function of the B-cell and T-cell
responses to the preS1 domain in the restoration of
anti-HBV immunity is under investigation. In sum-
mary, preS1-polypeptide vaccine can reverse HBV
tolerance in HBV carrier mice and may serve as a
potentially effective therapeutic strategy for treating
CHB infection.
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